Eyebio

Eyebio company information, Employees & Contact Information

Explore related pages

Eyebio email format Eyebio management contacts

Related company profiles:

EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.

Company Details

Employees
68
Founded
-
Address
London, Gb
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
https://eyebiotech.com/
Keywords
ophthalmology, biopharmaceuticals, biotechnology.
HQ
London
Competitors
Prima Mente, MSD, BIOW, Astoriom, Ensocell, Amber Therapeutics, Nordberg Medical, Reshape Biotech, Centillion, CellClar CIC.
Looking for a particular Eyebio employee's phone or email?

Eyebio Questions

News

Merck to acquire Eyebiotech in deal worth up to $3B - Eyes On Eyecare

Merck to acquire Eyebiotech in deal worth up to $3B Eyes On Eyecare

Merck completes acquisition of EyeBio - Ophthalmology Times

Merck completes acquisition of EyeBio Ophthalmology Times

Merck to buy eye-focused drug developer EyeBio for as much as $3 bln - Reuters

Merck to buy eye-focused drug developer EyeBio for as much as $3 bln Reuters

Merck & Co. sees clear vision to new ophthalmology assets with $3B EyeBio buy - Fierce Biotech

Merck & Co. sees clear vision to new ophthalmology assets with $3B EyeBio buy Fierce Biotech

in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema - Business Wire

in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema Business Wire

EyeBio announces expansion of Series A to $130 Million, advances development of Restoret for retinal diseases - Modern Retina

EyeBio announces expansion of Series A to $130 Million, advances development of Restoret for retinal diseases Modern Retina

MSD grabs Eyebiotech Ltd for US$1.3bn upfront - European Biotechnology Magazine

MSD grabs Eyebiotech Ltd for US$1.3bn upfront European Biotechnology Magazine

Merck To Pay as Much as $3 Billion for Eye Treatment Startup - Bloomberg

Merck To Pay as Much as $3 Billion for Eye Treatment Startup Bloomberg

Merck Sees Pipeline Diversification Opportunity in $1.3B EyeBio Acquisition - MedCity News

Merck Sees Pipeline Diversification Opportunity in $1.3B EyeBio Acquisition MedCity News

Wet-Age Related Macular Degeneration Market to Observe Stupendous Growth by 2032, Predicts DelveInsight | Key Players - AbbVie, Opthea, AffaMed Therapeutics, EyeBiotech, Novartis, Hoffmann-La Roche, Kyowa Kirin, Skyline Therapeutics - Yahoo Finance

Wet-Age Related Macular Degeneration Market to Observe Stupendous Growth by 2032, Predicts DelveInsight | Key Players - AbbVie, Opthea, AffaMed Therapeutics, EyeBiotech, Novartis, Hoffmann-La Roche, Kyowa Kirin, Skyline Therapeutics Yahoo Finance

EyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team - Business Wire

EyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team Business Wire

Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports - Reuters

Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports Reuters

EyeBiotech Ltd. raises $65 million to develop new eye disease therapies - Ophthalmology Times

EyeBiotech Ltd. raises $65 million to develop new eye disease therapies Ophthalmology Times

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases - Business Wire

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases Business Wire

Merck to acquire EyeBio for upfront payment of $1.3 billion - Ophthalmology Times

Merck to acquire EyeBio for upfront payment of $1.3 billion Ophthalmology Times

Eyebiotech Limited introduces first retinal disease candidate - Eyes On Eyecare

Eyebiotech Limited introduces first retinal disease candidate Eyes On Eyecare

EyeBio presents positive data on Restoret from AMARONE trial for DME and wet AMD - Eyes On Eyecare

EyeBio presents positive data on Restoret from AMARONE trial for DME and wet AMD Eyes On Eyecare

EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting - Business Wire

EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting Business Wire

First patients dosed in Phase 1b/2 trial of EYE103 in nAMD, DME - Ophthalmology Times

First patients dosed in Phase 1b/2 trial of EYE103 in nAMD, DME Ophthalmology Times

Pharma MNCs eye biotech sector - China Daily

Pharma MNCs eye biotech sector China Daily

Labor takes $27m stake in breakthrough eye biotech - AFR

Labor takes $27m stake in breakthrough eye biotech AFR

Companies like Eyebio

Ensocell logo - Similar company to Eyebio

Ensocell

19
Nordberg Medical logo - Similar company to Eyebio

Nordberg Medical

103
CellClar CIC logo - Similar company to Eyebio

Cellclar Cic

14
MSD logo - Similar company to Eyebio

Msd

40.39K
Centillion logo - Similar company to Eyebio

Centillion

18
BIOW logo - Similar company to Eyebio

Biow

87
Astoriom logo - Similar company to Eyebio

Astoriom

38
Prima Mente logo - Similar company to Eyebio

Prima Mente

18
Reshape Biotech logo - Similar company to Eyebio

Reshape Biotech

70
Amber Therapeutics logo - Similar company to Eyebio

Amber Therapeutics

45

Top Eyebio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant